Last updated: September 24, 2026
Glipizide is a mature, multisource sulfonylurea with limited opportunities for conventional generic differentiation. The strongest commercial opportunities are in controlled-release performance, dose flexibility, low-cost manufacturing, adherence-oriented packaging, and combination products. Excipient selection must address glipizide’s low aqueous solubility, food-related absorption variability, dose-dependent hypoglycemia risk, and the release-control requirements of extended-release tablets.
What is the current FDA status of glipizide?
Glipizide is an FDA-approved oral antidiabetic drug used with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is marketed in immediate-release and extended-release tablets.
| Product type |
Common strengths |
Administration |
Primary formulation objective |
| Immediate-release glipizide |
5 mg, 10 mg |
Approximately 30 minutes before meals |
Rapid and reproducible disintegration and dissolution |
| Extended-release glipizide |
2.5 mg, 5 mg, 10 mg |
Once daily with breakfast |
Controlled delivery over the dosing interval |
| Combination products |
Historically glipizide/metformin products |
Meal-associated dosing |
Combination therapy and adherence |
The original Glucotrol and Glucotrol XL products were developed by Pfizer. Multiple generic manufacturers now market glipizide tablets. FDA labeling identifies glipizide as a sulfonylurea that stimulates pancreatic insulin release and carries a clinically important risk of hypoglycemia, particularly in patients with irregular food intake, renal impairment, hepatic impairment, or excessive dosing (U.S. Food and Drug Administration [FDA], 2018a, 2018b).
Glipizide is a small-molecule generic drug, not a biologic. Biosimilar risk is therefore not applicable. Competitive pressure comes from generic tablets, metformin, newer branded therapies, and other low-cost sulfonylureas.
What excipients are used in immediate-release glipizide tablets?
Immediate-release glipizide requires excipients that support uniform low-dose drug distribution, rapid tablet breakup, acceptable hardness, and consistent dissolution.
Representative excipient classes include:
| Excipient class |
Typical examples |
Function in glipizide immediate-release tablets |
| Diluent |
Microcrystalline cellulose, lactose, dibasic calcium phosphate |
Provides tablet mass and improves compressibility |
| Disintegrant |
Starch, sodium starch glycolate, crospovidone, croscarmellose sodium |
Promotes rapid tablet breakup |
| Binder |
Povidone, pregelatinized starch, hydroxypropyl cellulose |
Improves granule and tablet strength |
| Glidant |
Colloidal silicon dioxide |
Improves powder flow and content uniformity |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Reduces ejection force and tooling friction |
| Film coating |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Supports appearance, identification, and swallowability |
The reference Glucotrol immediate-release label lists lactose, microcrystalline cellulose, starch, magnesium stearate, and colloidal silicon dioxide among its inactive ingredients, although generic products may use different excipient systems (FDA, 2018a).
Why content uniformity matters
Glipizide tablets contain relatively low drug loads. A formulation that uses direct compression must maintain adequate blend uniformity despite differences in particle size, density, electrostatic behavior, and segregation tendency. Roller compaction or wet granulation can reduce segregation risk but may increase process complexity and affect dissolution.
For a generic developer, the primary technical targets are:
- Assay and content uniformity across the batch.
- Rapid disintegration without excessive tablet friability.
- Dissolution similarity to the reference product.
- Low lubricant sensitivity.
- Stable performance after exposure to humidity.
- Reproducible manufacturing at 5 mg and 10 mg strengths.
A high-solubility excipient system is not necessarily required if the product meets dissolution specifications. Glipizide’s low solubility, however, makes excessive hydrophobic lubrication, overcompression, and poor wetting commercially relevant risks.
What excipients are used in extended-release glipizide?
Extended-release glipizide products use a matrix or osmotic-release architecture rather than a conventional rapidly disintegrating tablet. Glucotrol XL is an osmotic tablet system. The tablet releases glipizide through a delivery orifice as water enters the core and generates osmotic pressure. The tablet shell may pass through the gastrointestinal tract and appear in the stool as a hydrated shell or “ghost tablet” (FDA, 2018b).
Representative excipient categories include:
| Functional component |
Representative materials |
Commercial role |
| Osmotic agent |
Sodium chloride and other osmotically active materials |
Drives water influx and drug delivery |
| Matrix or tablet-forming polymer |
Polyethylene oxide, hypromellose |
Controls hydration, swelling, and release |
| Diluent |
Lactose, microcrystalline cellulose |
Adjusts tablet mass and compressibility |
| Pore-forming or release-modifying material |
Water-soluble excipients and polymers |
Controls release rate |
| Coating polymer |
Cellulosic film formers |
Protects the core and supports release-system integrity |
| Lubricant and glidant |
Magnesium stearate, colloidal silicon dioxide |
Enables manufacturing |
| Colorant |
Iron oxides or other approved pigments |
Product identification |
The exact formulation of each generic extended-release product is manufacturer-specific. A generic applicant cannot treat the label excipient list as proof of formulation equivalence. Comparative dissolution, pharmacokinetics, in vitro release characterization, and stability data determine whether the product performs adequately.
How should a company design an excipient strategy for glipizide?
A practical strategy should separate the immediate-release and extended-release products rather than use one platform for both.
Immediate-release strategy
For immediate-release tablets, the lowest-cost approach is usually a robust direct-compression or dry-granulation platform using:
- Microcrystalline cellulose or another compressible filler.
- A fast disintegrant.
- Minimal hydrophobic lubricant.
- A glidant to control flow.
- A simple film coat for identification.
Direct compression can reduce manufacturing steps and solvent use. Dry granulation may be preferable when the active pharmaceutical ingredient has poor flow or segregation behavior. Wet granulation is less attractive where the drug or excipient system creates moisture-related stability or dissolution risks.
The formulation should avoid excessive polymer content. A dense hydrophilic matrix can slow release and create dissolution variability that is unnecessary for an immediate-release product.
Extended-release strategy
For extended-release tablets, the primary commercial asset is release-system reproducibility. Candidate platforms include:
- Hydrophilic matrix tablets using hypromellose or polyethylene oxide.
- Osmotic systems using an osmogen, semipermeable membrane, and precision delivery orifice.
- Multiparticulate systems using coated pellets or mini-tablets.
- Geomatrix or multilayer tablets that combine immediate and sustained-release zones.
A hydrophilic matrix is generally less complex and less expensive than an osmotic system. An osmotic system can provide tighter release control but requires specialized coating, drilling, process controls, and in-process testing. Multiparticulates may reduce sensitivity to gastrointestinal transit and enable sprinkle or capsule presentations, but they introduce more complex coating and dose-uniformity requirements.
The most attractive platform depends on the target claim. A company seeking a low-cost generic should prioritize manufacturing simplicity and bioequivalence. A company seeking differentiated intellectual property should consider a multiparticulate, abuse-resistant, flexible-dose, or combination-release product.
What formulation patents can protect a glipizide product?
Glipizide’s active ingredient and basic tablet products are mature technologies. The principal patent opportunities are formulation and manufacturing claims rather than new-molecule claims.
Potentially protectable subject matter includes:
- Specific polymer ratios for extended release.
- Osmotic core and membrane compositions.
- Delivery-orifice dimensions and manufacturing methods.
- Multiparticulate coating structures.
- Immediate-release and extended-release bilayer tablets.
- Improved dissolution under fed and fasted conditions.
- Reduced food effect.
- Improved stability under high humidity.
- Pediatric or dysphagia-friendly dosage forms.
- Fixed-dose combinations with metformin or other antidiabetic agents.
- Continuous manufacturing or solvent-reduced production methods.
A formulation patent must provide a measurable technical distinction. Claims based only on substituting one conventional filler for another are vulnerable to obviousness challenges unless the substitution produces an unexpected dissolution, stability, manufacturability, or pharmacokinetic result.
What is the Orange Book status of glipizide?
Glipizide is a multisource generic drug with immediate-release and extended-release dosage forms. The principal competitive issue is abbreviated new drug application approval and bioequivalence, not branded patent exclusion.
For generic applicants, the relevant regulatory pathway is generally an ANDA supported by:
- Pharmaceutical equivalence.
- Comparative dissolution.
- Stability data.
- Bioequivalence, where required.
- Manufacturing controls.
- Labeling consistent with the reference product.
The Orange Book remains the controlling source for current reference-listed drug status, therapeutic equivalence codes, and any patent or exclusivity entries. Older glipizide products do not create a meaningful new chemical entity exclusivity barrier. Any commercial diligence should distinguish the immediate-release reference product from the extended-release reference product because approval requirements and formulation risks differ (FDA, 2024).
When does glipizide lose exclusivity?
Glipizide lost practical market exclusivity decades ago. Generic entry has already occurred across immediate-release and extended-release tablets. There is no commercially meaningful new chemical entity exclusivity remaining for the active ingredient.
The relevant barriers are:
- Current ANDA approval timing.
- Product-specific bioequivalence.
- Manufacturing capacity.
- Therapeutic-equivalence substitution.
- State-level substitution rules.
- Formulation patents, if any remain enforceable for a specific product.
- Commercial contracting with wholesalers, pharmacy benefit managers, and health systems.
Because glipizide is an established generic, a new entrant is unlikely to obtain premium pricing based solely on the active ingredient. The economic case depends on cost position, supply reliability, dosage-form differentiation, or combination-product strategy.
What generic entry risks exist for glipizide extended-release products?
Extended-release products carry greater development risk than immediate-release tablets. The principal risks are:
- Failure to match the reference release profile.
- Food-related pharmacokinetic differences.
- Dose dumping under altered pH or mechanical stress.
- Variable hydration and polymer swelling.
- Inconsistent coating weight or membrane permeability.
- Inadequate tablet strength after drilling or coating.
- Excessive residual drug release after the intended dosing interval.
- Confusion caused by visible tablet remnants in stool.
An extended-release product can meet a basic dissolution specification yet show clinical or regulatory problems if its release mechanism is sensitive to meal composition, gastrointestinal pH, agitation, or transit time. A robust development program should use discriminatory dissolution methods, pH-shift testing, alcohol challenge where relevant, mechanical stress testing, and fed-versus-fasted pharmacokinetic assessment.
Which commercial opportunities are most attractive?
The best opportunities are targeted reformulations rather than another conventional 5 mg or 10 mg tablet.
1. Lower-cost extended-release manufacturing
A hydrophilic matrix platform could compete with osmotic products on manufacturing cost if it provides acceptable release similarity and pharmacokinetics. The value proposition is supply reliability and lower unit cost, not premium pricing.
2. Combination products
Glipizide/metformin products can reduce pill burden, but the combination faces competition from inexpensive separate tablets and newer diabetes therapies. Commercial success would require a meaningful advantage in adherence, dose flexibility, packaging, or formulary economics.
3. Flexible-dose products
A scored tablet, multiparticulate capsule, or dosage form supporting smaller titration steps could address hypoglycemia management and dose adjustment. Any score-line claim must be supported by dose-uniformity data after splitting.
4. Patient-friendly dosage forms
Orally disintegrating tablets, sprinkle capsules, or mini-tablets could target patients with dysphagia or swallowing difficulty. Taste masking is less important than for pediatric medicines because glipizide is primarily an adult product, but mouthfeel and stability remain development issues.
5. Adherence packaging
Calendar blister packs, breakfast-linked packaging, and combination adherence packs may offer commercial value without changing the formulation. The opportunity is strongest in cash-pay, Medicare, and health-system channels where low-cost adherence interventions can reduce treatment disruption.
6. Emerging-market supply
Glipizide remains relevant where newer glucose-lowering agents are unaffordable or unavailable. Products designed for hot, humid distribution environments can differentiate through packaging, moisture protection, and long-term stability rather than novel excipients.
How does glipizide compare with competing diabetes drugs?
| Attribute |
Glipizide |
Metformin |
DPP-4 inhibitors |
SGLT2 inhibitors |
| Drug class |
Sulfonylurea |
Biguanide |
DPP-4 inhibitor |
SGLT2 inhibitor |
| Generic maturity |
High |
High |
Mixed, depending on product |
Lower for many products |
| Main formulation opportunity |
Release control and combinations |
Extended release and combinations |
Branded or generic differentiation |
Formulation and combination products |
| Hypoglycemia risk |
Clinically significant |
Low as monotherapy |
Low |
Low |
| Cost position |
Low |
Low |
Moderate to high |
Moderate to high |
| Main commercial weakness |
Hypoglycemia and weight gain |
Gastrointestinal intolerance |
Cost |
Cost and tolerability considerations |
Glipizide’s low price is its principal competitive advantage. Its main clinical disadvantages limit the premium available for formulation innovation. A new product must therefore create operational or adherence value that payers and patients can recognize.
What patent litigation and Paragraph IV risks affect glipizide?
Glipizide has no meaningful current new-molecule Paragraph IV landscape comparable to recently launched branded drugs. For a new generic, Paragraph IV exposure would mainly arise from any unexpired formulation or method-of-use patent listed against a specific reference product.
The more relevant legal risks are:
- Patent infringement claims involving extended-release architecture.
- Trade-secret disputes involving manufacturing processes.
- ANDA labeling or indication disputes.
- Product liability exposure related to hypoglycemia.
- Design-around challenges involving osmotic delivery systems.
- Antitrust or market-allocation concerns in settlement agreements.
A settlement agreement involving glipizide would have limited commercial significance unless it covered a differentiated extended-release product, a major combination product, or a manufacturing platform used across multiple drugs.
Key Takeaways
- Glipizide is a mature generic drug with no practical new chemical entity exclusivity barrier.
- Immediate-release opportunities center on content uniformity, rapid disintegration, low-cost processing, and moisture stability.
- Extended-release products create greater technical and regulatory value because release control, food effects, and manufacturing complexity are material.
- Hydrophilic matrix systems may offer a lower-cost alternative to osmotic delivery, while osmotic systems may support stronger formulation differentiation.
- The strongest patent opportunities involve release mechanisms, multiparticulates, combination products, manufacturing processes, and improved stability.
- Biosimilar risk is irrelevant because glipizide is a small molecule.
- Commercial success depends on cost, supply reliability, adherence design, and dosage-form differentiation rather than active-ingredient exclusivity.
FAQs
Can glipizide be formulated as an orally disintegrating tablet?
Yes. An orally disintegrating tablet could target patients with swallowing difficulty, but rapid disintegration must not compromise dose uniformity or create unacceptable taste and mouthfeel. The product would need a clear adherence or access advantage over standard tablets.
Is glipizide suitable for a transdermal or injectable product?
Commercially, the case is weak. Glipizide is used as an oral insulin secretagogue, and a nonoral product would add development cost, delivery complexity, and safety concerns without an obvious therapeutic advantage.
Which excipient is most important in glipizide extended-release tablets?
The release-controlling polymer system is usually the most important excipient element. In osmotic systems, the osmogen, membrane, and delivery-orifice design are equally important to release performance.
Can a company obtain new patents on a glipizide formulation?
Yes. Patent protection may be available for a genuinely distinct dosage form, polymer architecture, manufacturing method, combination product, or performance improvement. Conventional substitution of fillers or lubricants is less likely to support durable protection.
Is glipizide an attractive target for a branded reformulation?
Only in a focused niche. A branded reformulation would need a defensible advantage such as improved release consistency, reduced food effect, flexible dosing, adherence support, or a clinically useful fixed-dose combination. A standard once-daily tablet alone is unlikely to support premium pricing in a mature generic market.
References
-
U.S. Food and Drug Administration. (2018a). Glucotrol (glipizide) tablets: Prescribing information. Pfizer Laboratories.
-
U.S. Food and Drug Administration. (2018b). Glucotrol XL (glipizide extended-release tablets): Prescribing information. Pfizer Laboratories.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2022). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2020). Product-specific guidance for generic drug development: Glipizide tablets and extended-release tablets. U.S. Department of Health and Human Services.
